glomerular disease
Advertisement
NOBLE examined the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3G or IC-MPGN.
Oral iptacopan (Fabhalta) has become the first FDA-approved treatment for proteinuria in adults with C3 glomerulopathy.
Researchers wanted to understand kidney changes with O. felineus infection and whether there is an association with IgAN.
Researchers reported the progression of kidney function throughout the course of IgA nephropathy.
Are immunosuppressive therapies used to treat glomerular disease are related to higher cardiovascular risks?
Travere will submit an application to the FDA requesting approval of sparsentan for focal segmental glomerulosclerosis.
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
A study examined the association of APOL1 risk variants and genotypes with chronic kidney disease among West Africans.
Carla Nester spoke about two presentations at Kidney Week focused on potential therapies for C3 glomerulopathy.
Researchers compared incidence of mortality and kidney failure between patients with CKD and rare kidney diseases.
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
Pegcetacoplan achieved significant reductions in proteinuria and C3c staining and stabilized eGFR in patients with C3G.
Lupkynis for lupus nephritis is the focus of six accepted abstracts at the American Society of Nephrology Kidney Week 2024.
The American Society of Nephrology has launched the Glomerular Diseases Collaborative.
Columbia University will use a $20M gift to establish the David Koch Jr. Glomerular Kidney Center.
Researchers examined data of patients starting kidney replacement therapy for ESRD due to primary glomerular disease.
The VALIANT phase 3 trial produced positive results for the use of systemic pegcetacoplan in patients with C3G or IC-IMPGN.
Iptacopan with supportive care resulted in a notable reduction in proteinuria in patients with C3 glomerulopathy.
Martin Pollak reflected on winning the David M. Hume Memorial Award and on breakthroughs in glomerular diseases.
A team developed a machine learning classifier for 12 classes of glomerulonephritis.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.